Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?

por Del Campo Milan, Marta, Zuroff, Leah, Jimenez, Connie R., Scheltens, Philip, Teunissen, Charlotte E.
Publicado 2015

CSF proteomic signature predicts progression to Alzheimer's disease dementia

por Vromen, Eleonora M., del Campo Milán, Marta, Scheltens, Philip, Teunissen, Charlotte E., Visser, Pieter Jelle, Tijms, Betty M.
Publicado 2022

Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia

por Chakraborty, Ananya, Chatterjee, Madhurima, Twaalfhoven, Harry, Del Campo Milan, Marta, Teunissen, Charlotte E., Scheltens, Philip, Fontijn, Ruud D., van Der Flier, Wiesje M., de Vries, Helga E.
Publicado 2018

Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders

por Vijverberg, Everard G.B., Dols, Annemiek, Krudop, Welmoed A., Del Campo Milan, Marta, Kerssens, Cora J., Gossink, Flora, Prins, Niels D., Stek, Max L., Scheltens, Philip, Teunissen, Charlotte E., Pijnenburg, Yolande A.L.
Publicado 2017